Premium
Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival
Author(s) -
Kirrander Peter,
Sherif Amir,
Friedrich Bengt,
Lambe Mats,
Håkansson Ulf
Publication year - 2016
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.12993
Subject(s) - medicine , penile cancer , relative survival , incidence (geometry) , lymph node , population , stage (stratigraphy) , penis , cancer , surgery , gynecology , cancer registry , paleontology , physics , environmental health , optics , biology
Objectives To assess penile cancer incidence, stage distribution, adherence to guidelines and prognostic factors in a population‐based setting. Patients and Methods The population‐based Swedish National Penile Cancer Register ( NPECR ) contains detailed information on tumour characteristics and management patterns. A total of 1 678 men with primary squamous cell carcinoma of the penis identified in the NPECR between 2000 and 2012 were included in the study. Results The mean age‐adjusted incidence of penile cancer was 2.1/100 000 men, remaining virtually unchanged during the study period. At diagnosis, 14 and 2% of the men had clinical N+ and M+ disease, respectively. Most men were staged pT is (34%), pT 2 (19%), or pT 1 (18%), while stage information was unavailable for 18% of the men. Organ‐preserving treatment was used in 71% of Tis–T1 tumours. Of men with cN 0 and ≥ pT 1G2 disease, 50% underwent lymph node staging, while 74% of men with cN 1–3 disease underwent lymph node dissection. The overall 5‐year relative survival rate was 82%. Men aged ≥40 years and those with pT 2–3, G2–3 and N+ tumours had worse outcomes. Conclusions The incidence of penile cancer in Sweden is stable. Most men presented with localized disease, and the proportion of non‐invasive tumours was high. During the period under study, adherence to guidelines was suboptimum. The overall 5‐year relative survival rate was 82%. Older age, increasing tumour stage and grade, and increasing lymph node stage were associated with poorer survival.